Regeneron Pharmaceuticals traded at $595.40 this Friday July 1st, increasing $4.27 or 0.72 percent since the previous trading session. Looking back, over the last four weeks, Regeneron Pharmaceuticals gained 5.60 percent. Over the last 12 months, its price rose by 2.01 percent. Looking ahead, we forecast Regeneron Pharmaceuticals to be priced at 579.26 by the end of this quarter and at 533.44 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Kyowa Hakko Kirin 3,080.00 45.00 1.48% -23.38%
Astellas Pharma 2,095.50 37.00 1.80% 9.08%
AbbVie 153.80 0.64 0.42% 33.54%
Agenus 1.96 0.02 1.03% -64.49%
Agios Pharmaceuticals 23.36 1.19 5.37% -58.08%
Alimera Sciences 5.46 -0.01 -0.18% -39.47%
Alnylam Pharmaceuticals 148.25 2.40 1.65% -13.52%
Amgen 245.55 2.25 0.92% -1.27%
AstraZeneca 10,808.00 54.00 0.50% 24.54%
Biogen 210.63 6.69 3.28% -39.60%
Bluebird Bio 4.28 0.14 3.38% -86.36%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Esperion Therapeutics 6.45 0.09 1.42% -68.52%
Gilead Sciences 62.36 0.55 0.89% -10.01%
GlaxoSmithKline 1,802.60 17.00 0.95% 25.84%
Intercept Pharmaceuticals 14.13 0.32 2.32% -29.31%
Incyte Corp 77.67 1.70 2.24% -7.07%
Ionis Pharmaceuticals 38.06 1.04 2.81% -4.66%
J&J 179.52 2.01 1.13% 6.24%
Eli Lilly 324.71 0.48 0.15% 38.79%
Merck & Co 92.42 1.25 1.37% 17.58%
Moderna Inc 149.95 7.10 4.97% -36.00%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Novartis 81.65 1.32 1.64% -3.02%
Novartis 84.36 -0.17 -0.20% -8.28%
Iveric bio Inc. 9.40 -0.22 -2.29% 18.39%
Opthea Ltd 1.17 -0.03 -2.09% -7.14%
Puma Biotechnology 2.78 -0.07 -2.46% -68.48%
Pfizer 52.31 -0.12 -0.23% 31.66%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Roche Holding 322.10 1.70 0.53% -8.06%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Sanofi 51.01 0.98 1.96% -2.60%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Teva Pharmaceutical Industries Ltd 2,746.00 -16.00 -0.58% -14.64%
United Therapeutics 238.00 2.36 1.00% 29.12%
Vertex Pharmaceuticals 287.32 5.53 1.96% 43.27%

Indexes Price Day Year
US500 3845 0 0% -11.47%
USND 11128 99.11 0.90% -23.99%
USNDX 11693 -28.10 -0.24% -20.92%

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.